 |
Anacor Pharmaceuticals Reports First Quarter 2012 Financial Results
May 10, 2012
|
17.0 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial
results for the first quarter ended March 31, 2012.
"Our Phase 3 trials of tavaborole in onychomycosis are progressing well,
with retention and compliance rates performing better than our
assumptions. We are looking forward to reporting data from our first
Phase 3 trial in January 2013," said David Perry, CEO of Anacor
...
|
|
Anacor Pharmaceuticals to Present Clinical Data on Tavaborole and AN2728 at Upcoming Medical Meetings
May 4, 2012
|
8.2 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will be
presenting clinical data on its lead compounds, tavaborole and AN2728,
at the following upcoming medical meetings:
72nd Society for Investigative Dermatology Annual Meeting — Thursday,
May 10, 2012
"Safety and Efficacy of AN2728 and AN2898 Ointments in a Phase 2a
...
|
|
Anacor Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call and Webcast
May 4, 2012
|
7.0 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results
for the quarter ended March 31, 2012, on Thursday, May 10, 2012 at
approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be
followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during
which management will discuss the company's financial results and recent
developments. The call can be accessed by dialing (877) 291-1...
|
|
Anacor Pharmaceuticals to Present at the Deutsche Bank Annual Health Care Conference
May 1, 2012
|
6.5 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry,
the company's Chief Executive Officer, will provide a company overview
at the Deutsche Bank Annual Health Care Conference on Monday May 7, 2012
at 4:10 p.m. ET in Boston, Massachusetts.
The event will be webcast live and may be accessed under "Events and
Presentations" on the Investors page of Anacor's website at www.ana...
|
|
Anacor Pharmaceuticals Reports 2011 Fourth Quarter and Year-End Financial Results
Mar 13, 2012
|
22.7 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial
results for the fourth quarter and year ended December 31, 2011.
"In 2011, we completed enrollment in two Phase 3 trials of tavaborole in
onychomycosis, which keeps us on track to announce top-line data from
the first of these trials around the end of 2012 and from the second
trial in the beginning of 2013," said David Perry...
|
|
Anacor Pharmaceuticals Announces Commencement of Phase 1 Clinical Trials of Boron-Based Compound for Sleeping Sickness
Mar 12, 2012
|
9.2 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC), announced today that its
collaboration partner, the
Drugs for Neglected Diseases initiative (DNDi), has commenced Phase
1 clinical studies of SCYX-7158 (also referred to as AN5568), the first
new oral drug candidate discovered specifically to combat human African
trypanosomiasis (HAT), also known as sleeping sickness. AN5568 was
discovered utilizing Anacor's b...
|
|
Anacor Pharmaceuticals Announces Fourth Quarter and Year End 2011 Financial Results Conference Call and Webcast
Mar 6, 2012
|
7.1 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results
for the fourth quarter and year ended December 31, 2011, on Tuesday
March 13, 2012 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The
announcement will be followed by a conference call at 5:00 p.m. ET /
2:00 p.m. PT during which management will discuss the company's
financial results and recent developments. The call can be accessed by
...
|
|
Anacor Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 15, 2012
|
6.8 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals announced today that David Perry, the company's
Chief Executive Officer, will provide a company overview at the
following upcoming investor conferences:
Citi Global Health Care Conference on Monday February 27, 2012 at
11:30 a.m. ET in New York, New York.
RBC Global Healthcare Conference on Tuesday February 28, 2012 at 8:00
...
|
|
Anacor Pharmaceuticals Announces the Sale of 3.25 Million Shares of Common Stock
Feb 8, 2012
|
7.1 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (Nasdaq:ANAC), today announced the sale of 3.25
million shares of its common stock for gross proceeds of $21,450,000
pursuant to an underwriting agreement with Canaccord Genuity acting as
the sole bookrunner. In addition, the Company has granted the
underwriters a 30-day option to purchase up to an additional 487,500
shares of common stock to cover over-allotments, if any.
...
|
|
Anacor Pharmaceuticals Announces Positive Preliminary Results from Two Safety Studies of AN2728 and Updates Atopic Dermatitis Results and Regulatory Status
Feb 7, 2012
|
57.0 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today positive
preliminary results from two safety studies of AN2728 - a maximal use
systemic exposure (MUSE) study in psoriatic patients and a local
tolerability study. The results of these two studies demonstrate that
AN2728 Ointment, 2% appears to be safe and well-tolerated when applied
to very large body surface areas and that it is well-tolerated when
...
|
|
Anacor Pharmaceuticals Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK ‘052 Phase 1 and 2 Clinical Trials
Feb 6, 2012
|
7.6 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its partner
GlaxoSmithKline (GSK) has voluntarily paused enrollment in its current
clinical trials of GSK2251052 (GSK ‘052) due to a recently identified
microbiological finding in a small number of patients in the Phase 2b
trial of GSK ‘052 for the treatment of complicated urinary tract
infections (cUTI). GSK is in the process of obtaini...
|
|
Anacor Pharmaceuticals Completes Enrollment in Second of Two Phase 3 Trials of Tavaborole for Onychomycosis
Dec 22, 2011
|
6.9 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has
completed the enrollment of approximately 600 patients in the second of
its two Phase 3 trials of tavaborole (formerly known as AN2690), a
topical anti-fungal product candidate for the treatment of
onychomycosis, a fungal infection of the nail and nail bed that affects
approximately 35 million people in the United States.
...
|
|
Anacor Pharmaceuticals Announces Positive Preliminary Results from Phase 2a Trial of AN2728 and AN2898 in Atopic Dermatitis
Dec 12, 2011
|
57.9 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced positive preliminary
results from a Phase 2a trial of its two boron-based phosphodiesterase-4
(PDE-4) inhibitors, AN2728 and AN2898, in mild-to-moderate atopic
dermatitis, a chronic rash characterized by inflammation and itching.
The primary endpoint for both compounds was successfully achieved after
28 days of twice-daily treatment, with 64% of AN2728-treated...
|
|
Anacor Pharmaceuticals Reports Third Quarter 2011 Financial Results
Nov 10, 2011
|
21.4 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) reported today its accomplishments
and financial results for the third quarter ended September 30, 2011.
"In the third quarter, we focused on completing the enrollment of our
two Phase 3 trials of tavaborole, formerly known as AN2690, our topical
antifungal product for onychomycosis, preparing for our End of Phase 2
discussions with the FDA for AN2728 in...
|
|
Anacor Pharmaceuticals Completes Enrollment in First of Two Phase 3 Trials of AN2690 for Onychomycosis
Nov 9, 2011
|
8.4 KB |
| |
Tavaborole granted as generic name for AN2690
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has
completed enrollment in the first of two Phase 3 trials of tavaborole
(formerly known as AN2690), a topical anti-fungal product candidate for
the treatment of onychomycosis. Onychomycosis is a fungal infection of
the nail and nail bed that affects approximately 35 million peo...
|
|
Anacor Pharmaceuticals Announces Third Quarter 2011 Financial Results Conference Call and Webcast
Nov 3, 2011
|
6.8 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results
for the third quarter ended September 30, 2011, on Thursday November 10,
2011 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will
be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during
which management will discuss the company's financial results and recent
developments. The call can be accessed by diali...
|
|
Anacor Pharmaceuticals to Present at the 10th Annual Bio Investor Forum
Oct 21, 2011
|
6.4 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (Nasdaq:ANAC) announced today that David Perry,
the company's Chief Executive Officer, will provide a company overview
at the 10th Annual Bio Investor Forum at 10:30 a.m. PT on
Wednesday October 26, 2011 in San Francisco, California. The
presentation will be webcast live and may be accessed under "Events and
Presentations" on the Investors page of Anacor's website at www.anacor.com.
...
|
|
NIH Awards Funding to UCSF for the Discovery of Antimalarial Agents in Collaboration with Anacor Pharmaceuticals
Oct 11, 2011
|
7.5 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that the University
of California San Francisco (UCSF) has been awarded $718,136 in funding
from the National Institutes of Health (NIH) to discover and optimize
novel oxaboroles as antimalarial drugs in collaboration with Anacor
Pharmaceuticals. The NIH grant provides support for the period beginning
September 30, 2011 and ending September 29, 2012.
...
|
|
Anacor's Partner GlaxoSmithKline Awarded up to $94 Million in U.S. Government Funding to Support Development of GSK ‘052, a Novel Gram-negative Antibiotic Discovered by Anacor
Sep 7, 2011
|
10.3 KB |
| |
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its partner,
GlaxoSmithKline (GSK), has been awarded a contract with the U.S.
Department of Health and Human Services' (HHS) Biomedical Advanced
Research and Development Authority (BARDA) to support the ongoing
development of GSK2251052 (GSK ‘052, formerly AN3665), a novel
boron-based Gram-negative systemic antibiotic discovered by Anacor.
...
|
|
Anacor and GlaxoSmithKline Amend and Expand R&D Collaboration
Sep 6, 2011
|
8.9 KB |
| |
Anacor to receive $5 million upfront payment and up to an
additional $11.3 million in proceeds by year end 2012
PALO ALTO, Calif.--(BUSINESS WIRE)--
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has amended
and expanded its research and development collaboration with
GlaxoSmithKline (GSK) to provide GSK the option to extend its rights
around the bacterial enzyme target leucyl-tRNA synthetase (LeuRS), as
...
|
|
|
